Inflammaging: The Chronic Inflammation That Drives Every Aging Hallmark (2026)

At twenty-five, you sprain your ankle and the swelling resolves in a week. At sixty-five, your ankle might heal at a similar rate -- but your baseline has changed. Your blood carries elevated levels of inflammatory proteins that weren't there four decades ago. No infection. No injury. No autoimmune diagnosis. Just a slow, persistent inflammatory hum that gets louder every year.

This phenomenon has a name: inflammaging. And over the past two decades, it has moved from an obscure immunology concept to what many researchers now consider the central integrating mechanism of biological aging -- the process that connects virtually every hallmark of aging to the diseases that ultimately kill us.

TL;DR -- Key Takeaways

• Inflammaging is chronic, low-grade, sterile inflammation that increases with age -- coined by immunologist Claudio Franceschi in 2000
• Five major sources feed it: senescent cell SASP, gut barrier dysfunction, visceral fat secretions, mitochondrial DAMPs, and microbiome dysbiosis
• Key biomarkers: CRP, IL-6, TNF-alpha, IL-1beta -- elevated levels predict mortality better than cholesterol
• Inflammaging accelerates cardiovascular disease, neurodegeneration, cancer, sarcopenia, and metabolic syndrome
• The immune system paradox: aging produces both chronic inflammation (overactive innate immunity) and immunodeficiency (declining adaptive immunity) simultaneously
• Evidence-backed interventions: omega-3 fatty acids (SPM production), quercetin and fisetin (senolytic SASP reduction), resveratrol (NF-kappaB inhibition), exercise (the IL-6 paradox), caloric restriction, and berberine (AMPK activation)
• High-sensitivity CRP (hs-CRP) is the most accessible biomarker for tracking your inflammatory baseline

What Is Inflammaging?

In 2000, Italian immunologist Claudio Franceschi published a paper in Annals of the New York Academy of Sciences (PMID 10911963) that coined the term "inflammaging" to describe a phenomenon he and his colleagues had observed in centenarian studies: aging is accompanied by a chronic, progressive increase in pro-inflammatory status.

The concept distinguishes two fundamentally different types of inflammation:

Acute inflammation is the immune response you're familiar with -- redness, swelling, heat, pain. It's triggered by a specific threat (a pathogen, a wound), resolves when the threat is eliminated, and is essential for survival. Without it, a paper cut could kill you.

Chronic low-grade inflammation -- inflammaging -- is something else entirely. It's not triggered by a specific pathogen or injury. It doesn't resolve. It has no clear beginning. It produces no visible symptoms for years or decades. And it's not protective -- it's destructive.

The word "sterile" is key. Inflammaging occurs in the absence of infection. The immune system is responding to endogenous signals -- damage-associated molecular patterns (DAMPs, molecules released by stressed or dying cells that activate the innate immune system as if an infection were present), cellular debris, metabolic byproducts -- rather than external pathogens. Your body is inflaming itself.

Franceschi's original insight was that this chronic inflammatory state isn't just a consequence of aging -- it's a driver. The inflammation damages tissues, which releases more inflammatory signals, which damages more tissues. A self-amplifying loop with no off switch.

A 2018 review published in Ageing Research Reviews (Ferrucci and Fabbri, PMID 28624575) formalized this, showing that elevated inflammatory markers in otherwise healthy older adults predicted all-cause mortality, cardiovascular events, cognitive decline, and physical disability -- independently of any diagnosed disease.

You can be "healthy" by every standard clinical measure and still be inflamed -- and that inflammation is aging you.

The Five Sources of Inflammaging

Inflammaging doesn't have a single cause. It's fed by at least five distinct biological processes, all of which worsen with age and all of which amplify each other.

1. Senescent Cell SASP

Senescent cells -- damaged cells that stop dividing but refuse to die -- are arguably the single largest contributor to inflammaging. These "zombie cells" secrete a cocktail of inflammatory molecules called the SASP (Senescence-Associated Secretory Phenotype): interleukins (IL-6, IL-1beta), tumor necrosis factor alpha (TNF-alpha), chemokines (signaling proteins that recruit immune cells), and matrix metalloproteinases (MMPs -- enzymes that degrade the structural scaffolding between cells).

The SASP doesn't stay local. These inflammatory signals enter the bloodstream and create systemic inflammation. Worse, SASP signals can induce senescence in neighboring healthy cells -- a phenomenon researchers call paracrine senescence or the "bystander effect." Baker et al. (2016, Nature) demonstrated that transplanting a small number of senescent cells into young mice was sufficient to spread senescence throughout the body and reduce lifespan.

By age 60-80, senescent cells may represent 5-15% of cells in some tissues. Each one is a point source of inflammation. The cumulative SASP output across trillions of cells creates a measurable systemic inflammatory load.

2. Gut Barrier Dysfunction ("Leaky Gut")

Your intestinal lining is a single cell layer thick. It forms the largest barrier between your internal environment and the external world -- roughly 32 square meters of surface area that must simultaneously absorb nutrients and block pathogens.

With age, this barrier deteriorates. The tight junction proteins (claudins and occludins -- molecular fasteners that seal the gaps between intestinal cells) that hold intestinal epithelial cells together weaken. The mucus layer thins. The result: increased intestinal permeability, commonly called "leaky gut."

When the barrier fails, bacterial components -- particularly lipopolysaccharide (LPS), a molecule from the outer membrane of gram-negative bacteria -- translocate into the bloodstream. LPS is one of the most potent activators of the innate immune system. Even small amounts trigger Toll-like receptor 4 (TLR4) signaling, activating NF-kappaB (nuclear factor kappa-light-chain-enhancer of activated B cells -- the master switch for inflammatory gene expression) and driving production of IL-6, TNF-alpha, and IL-1beta.

Thevaranjan et al. (2017, Cell Host & Microbe) showed that aged mice had significantly higher circulating LPS and TNF-alpha than young mice -- and that this was driven by gut barrier dysfunction rather than changes in the microbiome alone. When they transplanted the aged microbiome into germ-free young mice, the young mice developed systemic inflammation only if gut barrier integrity was also compromised.

This process is sometimes called metabolic endotoxemia -- a chronic, low-level presence of bacterial toxins in the blood that keeps the immune system permanently activated.

For a deeper dive into the gut-aging connection, see The Gut Microbiome and Longevity.

3. Visceral Fat: The Endocrine Organ You Didn't Ask For

Not all fat is created equal. Subcutaneous fat (under the skin) is relatively metabolically inert. Visceral fat -- the fat packed around your abdominal organs -- is an active endocrine organ that secretes inflammatory cytokines (cell signaling proteins that regulate inflammation and immune responses) at an alarming rate.

Visceral adipose tissue contains a high proportion of macrophages (immune cells that engulf pathogens and debris). With age and weight gain, these macrophages shift from an M2 anti-inflammatory phenotype to an M1 pro-inflammatory phenotype. M1 macrophages produce large quantities of TNF-alpha, IL-6, and IL-1beta.

Hotamisligil (2006, Nature) established that obesity-driven inflammation is a key link between metabolic syndrome and aging. His group demonstrated that TNF-alpha produced by visceral fat directly causes insulin resistance -- creating a vicious cycle where inflammation drives metabolic dysfunction, which drives more fat accumulation, which drives more inflammation.

Visceral fat also produces resistin and leptin (hormones secreted by fat tissue that regulate appetite and metabolism), both of which have pro-inflammatory activity. And it produces less adiponectin -- an anti-inflammatory hormone that declines with increasing visceral fat mass.

The practical implication: waist circumference is a better predictor of inflammatory burden than BMI. You can be normal weight with high visceral fat (colloquially called "skinny fat" or TOFI -- Thin Outside, Fat Inside) and carry a significant inflammatory load.

4. Mitochondrial DAMPs

Mitochondria -- the organelles that produce cellular energy (ATP) -- have an evolutionary origin as bacteria. They retain their own circular DNA, distinct from nuclear DNA. This bacterial heritage has a consequence: when mitochondria are damaged and their contents leak into the cytoplasm or bloodstream, the immune system recognizes mitochondrial components as foreign.

These mitochondrial damage-associated molecular patterns (mtDAMPs) include:

• Mitochondrial DNA (mtDNA) -- recognized by TLR9, activating NF-kappaB
• N-formyl peptides -- recognized by formyl peptide receptors, recruiting neutrophils (a type of white blood cell that's first to arrive at sites of inflammation)
• Cardiolipin -- a mitochondrial membrane lipid that activates the NLRP3 inflammasome (a multiprotein complex inside cells that triggers the release of IL-1beta and IL-18 in response to danger signals)
• ATP and ROS -- reactive oxygen species (unstable molecules that damage cells when levels are too high) that activate additional inflammatory pathways

Zhang et al. (2010, Nature) first demonstrated that mitochondrial DAMPs released from injured cells activate innate immunity through the same pathways used to detect bacterial infection. This makes sense evolutionarily -- mitochondria were bacteria -- but it means that the mitochondrial dysfunction that accumulates with age is also a direct source of inflammatory signaling.

As mitochondrial quality control declines with age (through reduced mitophagy -- the selective autophagy process that identifies and recycles damaged mitochondria), damaged mitochondria accumulate and leak more DAMPs, feeding the inflammaging cycle. This connects inflammaging directly to the hallmarks of aging framework, where mitochondrial dysfunction is hallmark number six.

5. Dysbiotic Microbiome

The gut microbiome undergoes significant changes with age: reduced diversity, loss of beneficial species (particularly Bifidobacterium and butyrate-producing Faecalibacterium prausnitzii), and expansion of pro-inflammatory species (including certain Proteobacteria).

Butyrate (a short-chain fatty acid produced when gut bacteria ferment dietary fiber) is particularly important. It's the primary energy source for colonocytes (the cells lining the colon), maintains tight junction integrity, and has direct anti-inflammatory effects through inhibition of NF-kappaB and histone deacetylase (HDAC) activity. When butyrate-producing bacteria decline, colonocytes starve, barrier function deteriorates, and the anti-inflammatory brake is released.

Claesson et al. (2012, Nature) analyzed the microbiomes of 178 elderly individuals and found that microbiome composition correlated directly with health status, diet, and -- critically -- inflammatory markers. Those in long-term residential care (with less diverse diets) had less diverse microbiomes and higher inflammatory markers than community-dwelling individuals of the same age.

Biagi et al. (2016, Current Opinion in Biotechnology) extended this work to centenarians and semi-supercentenarians (105+), finding that extreme longevity was associated with a distinct microbiome signature: increased diversity and enrichment of specific health-associated taxa, suggesting that maintaining microbiome diversity may be both a marker and mechanism of successful aging.

The microbiome-inflammaging axis works in both directions: gut dysbiosis drives inflammation (through barrier dysfunction and loss of anti-inflammatory metabolites), and systemic inflammation reshapes the microbiome (inflammatory cytokines alter the intestinal environment, favoring inflammatory species). Another self-amplifying loop.

For a comprehensive look at this connection, see The Gut Microbiome and Longevity.

Key Takeaway: Inflammaging is driven by five converging sources: senescent cell SASP, gut barrier dysfunction (endotoxemia), mitochondrial DAMPs, accumulated cellular debris, and chronic immune activation. Understanding which sources are most active in your body — via biomarker testing — allows you to target interventions more precisely rather than taking a generic anti-inflammatory approach.

Watch: Bryan Johnson on the foods that keep you young and the oil that reduced inflammation by 85%:

The Key Biomarkers of Inflammaging

Unlike acute inflammation -- which produces obvious symptoms -- inflammaging is silent. The only way to detect it is through blood biomarkers.

C-Reactive Protein (CRP)

CRP is an acute-phase protein produced by the liver in response to IL-6 signaling. It's the most widely used clinical marker of systemic inflammation.

• Standard CRP tests detect levels above 10 mg/L (used to diagnose infections and acute inflammatory conditions)
• High-sensitivity CRP (hs-CRP) tests detect levels below 3 mg/L, which is the relevant range for inflammaging

The American Heart Association classifies cardiovascular risk by hs-CRP:

• < 1.0 mg/L: Low risk
• 1.0-3.0 mg/L: Moderate risk
• > 3.0 mg/L: High risk

Ridker et al. (2000, New England Journal of Medicine) demonstrated that hs-CRP predicts cardiovascular events independently of LDL cholesterol -- and that in some populations, hs-CRP is a better predictor than LDL.

Interleukin-6 (IL-6)

IL-6 is perhaps the most important cytokine in inflammaging. It's produced by senescent cells (SASP), visceral fat, activated macrophages, and T cells. It drives CRP production by the liver, promotes insulin resistance, accelerates muscle wasting, and has been called the "cytokine of gerontologists" because of its consistent association with age-related decline.

Ferrucci et al. (1999, Journal of the American Geriatrics Society) found that elevated IL-6 in older adults predicted disability onset, even after adjusting for current health status. It's not just a marker -- it's a mediator.

Normal serum IL-6: < 7 pg/mL. Optimal for longevity: likely < 2 pg/mL.

Tumor Necrosis Factor Alpha (TNF-alpha)

TNF-alpha is a master inflammatory cytokine produced primarily by macrophages. It activates NF-kappaB, induces insulin resistance, promotes muscle catabolism (breakdown), and can trigger apoptosis (programmed cell death) in some cell types. Elevated TNF-alpha is a hallmark of both visceral obesity and cellular senescence.

Drugs that block TNF-alpha (anti-TNF biologics) are among the most effective treatments for autoimmune diseases like rheumatoid arthritis and Crohn's disease -- which demonstrates just how destructive chronic TNF-alpha signaling can be.

Interleukin-1 Beta (IL-1beta)

IL-1beta is the primary output of the NLRP3 inflammasome. It's a potent pro-inflammatory cytokine that drives fever, tissue remodeling, and immune cell recruitment. In the context of inflammaging, IL-1beta is particularly relevant to atherosclerosis (the buildup of fatty plaques in arterial walls).

The CANTOS trial (Ridker et al., 2017, New England Journal of Medicine) -- a landmark 10,061-patient randomized controlled trial -- tested canakinumab, a monoclonal antibody that blocks IL-1beta, in patients with prior heart attacks and elevated CRP. The result: blocking IL-1beta reduced cardiovascular events by 15% and reduced lung cancer incidence significantly (with a notable reduction in overall cancer mortality) -- the first direct demonstration that anti-inflammatory therapy could prevent both heart disease and cancer in humans.

CANTOS is arguably the single most important clinical trial for the inflammaging hypothesis. It proved that chronic inflammation isn't just associated with age-related disease -- it causes it.

How Inflammaging Drives Age-Related Disease

Inflammaging isn't a disease itself. It's the substrate on which age-related diseases develop. Here's how it connects to the major killers.

Cardiovascular Disease

Atherosclerosis -- the process underlying heart attacks and strokes -- is fundamentally an inflammatory disease. The progression:

1. LDL cholesterol particles infiltrate the arterial wall
2. They become oxidized (modified by ROS)
3. Oxidized LDL activates endothelial cells, which recruit monocytes (a type of white blood cell that matures into macrophages)
4. Monocytes differentiate into macrophages and engulf oxidized LDL, becoming foam cells
5. Foam cells accumulate, forming the fatty streak -- the earliest visible atherosclerotic lesion
6. Foam cells secrete inflammatory cytokines (IL-6, TNF-alpha, IL-1beta), recruiting more immune cells
7. A fibrous cap forms over the lipid core
8. Inflammatory enzymes (MMPs) degrade the cap, making the plaque vulnerable to rupture
9. Plaque rupture triggers a blood clot -- heart attack or stroke

At every step, inflammation is the driver. Cholesterol provides the raw material, but inflammation determines whether that material becomes a lethal plaque. This is why the CANTOS trial -- which lowered inflammation without lowering cholesterol -- still reduced cardiovascular events.

Libby et al. (2002, Circulation) established the "inflammation hypothesis of atherosclerosis" that is now mainstream cardiology. The implication: managing inflammation may be as important as managing cholesterol for cardiovascular prevention.

Neurodegeneration

The brain has its own resident immune cells -- microglia -- that serve as sentinels, clearing debris and defending against pathogens. In the aging brain, microglia become chronically activated (a state called microglial priming), producing a constant stream of inflammatory cytokines and ROS.

This neuroinflammation is a central feature of both Alzheimer's and Parkinson's disease:

• In Alzheimer's, activated microglia cluster around amyloid-beta plaques, secreting IL-1beta and TNF-alpha that damage surrounding neurons. Heneka et al. (2015, Lancet Neurology) reviewed the evidence that neuroinflammation is not merely a response to amyloid plaques but an active contributor to disease progression -- and potentially a more tractable therapeutic target than amyloid itself.
• In Parkinson's, neuroinflammation in the substantia nigra (the brain region that produces dopamine) accelerates dopaminergic neuron loss. Epidemiological studies have consistently shown that long-term NSAID (non-steroidal anti-inflammatory drug) use is associated with reduced Parkinson's risk.

The blood-brain barrier (BBB -- a selective barrier that separates circulating blood from the brain) also becomes more permeable with age, allowing peripheral inflammatory signals to reach the brain. Systemic inflammaging doesn't stay in the periphery -- it reaches the central nervous system.

Cancer

The relationship between inflammation and cancer has been recognized since Rudolf Virchow first observed leukocytes in tumors in 1863. We now understand the mechanisms:

• Initiation: Inflammatory ROS damage DNA, creating mutations. Chronic inflammation in a tissue dramatically increases the mutation rate. Ulcerative colitis patients (chronic gut inflammation) have a 5-8x increased risk of colorectal cancer.
• Promotion: NF-kappaB activation promotes cell survival and proliferation. TNF-alpha activates NF-kappaB in pre-cancerous cells, preventing them from undergoing apoptosis. Grivennikov et al. (2010, Cell) called inflammation "a co-conspirator" in cancer development.
• Metastasis: Inflammatory cytokines promote angiogenesis (new blood vessel formation that feeds tumors), degrade the extracellular matrix (via MMPs from SASP), and create pre-metastatic niches -- distant tissue environments remodeled by inflammatory signals to be hospitable for incoming cancer cells.

The CANTOS trial's significant reduction in lung cancer incidence with IL-1beta blockade was not a surprise to cancer biologists -- it was confirmation of decades of mechanistic research.

Sarcopenia

Sarcopenia -- the progressive loss of skeletal muscle mass and strength with age -- is one of the strongest predictors of mortality in older adults. Inflammaging is a primary driver.

TNF-alpha and IL-6 directly promote muscle protein breakdown through activation of the ubiquitin-proteasome pathway (the cell's main protein degradation system) and inhibition of the mTOR pathway that drives muscle protein synthesis. The net effect: chronic inflammation shifts the balance from muscle building to muscle breakdown.

Schaap et al. (2006, Journal of Clinical Endocrinology & Metabolism) followed 2,177 older adults over five years and found that those with the highest IL-6 and CRP levels at baseline lost 2-3 times more muscle strength than those with the lowest levels -- independent of physical activity, diet, and chronic disease.

This creates another vicious cycle: muscle loss reduces the body's capacity for exercise, which reduces the anti-inflammatory benefit of physical activity, which allows inflammation to rise further, which accelerates muscle loss.

Metabolic Syndrome

The cluster of conditions known as metabolic syndrome -- insulin resistance, abdominal obesity, hypertension, dyslipidemia (abnormal blood fat levels) -- is tightly interwoven with inflammaging.

TNF-alpha directly impairs insulin receptor signaling by promoting serine phosphorylation of IRS-1 (insulin receptor substrate 1 -- a key protein in the insulin signaling cascade). IL-6 induces hepatic CRP production and promotes hepatic insulin resistance. The result: chronically elevated inflammatory cytokines make cells progressively less responsive to insulin.

As insulin resistance develops, the pancreas compensates by producing more insulin (hyperinsulinemia). Elevated insulin promotes fat storage -- particularly visceral fat -- which produces more inflammatory cytokines. The metabolic syndrome is, at its core, an inflammation-metabolism feedback loop.

The Immune System Paradox: Immunosenescence

One of the most counterintuitive aspects of aging is this: the immune system simultaneously becomes more inflammatory and less effective. This paradox has a name: immunosenescence.

The innate immune system (the rapid, non-specific first responder) becomes chronically activated. Macrophages and neutrophils produce more inflammatory cytokines at baseline but respond less effectively to actual threats. Natural killer cells increase in number but decrease in per-cell killing capacity.

The adaptive immune system (the targeted, memory-based response) deteriorates more dramatically:

• Thymic involution: The thymus (the organ that produces T cells -- immune cells that coordinate the adaptive immune response) begins shrinking after puberty and is largely replaced by fat tissue by age 50. New T cell production drops to roughly 5% of its peak.
• T cell exhaustion: The existing T cell pool becomes increasingly dominated by memory T cells that have been repeatedly stimulated. These cells express exhaustion markers (PD-1, CTLA-4) and produce more inflammatory cytokines but respond poorly to new threats.
• CMV burden: Cytomegalovirus (CMV -- a common herpesvirus that infects 50-80% of adults and persists lifelong) is a major driver of T cell exhaustion. The immune system devotes an increasingly large fraction of its T cell repertoire to suppressing CMV, leaving fewer cells available for other threats. Pawelec et al. (2005, Immunity & Ageing) described CMV as a key driver of the "immune risk profile" that predicts mortality in elderly populations.
• B cell decline: Antibody diversity decreases, vaccine responses weaken, and the ratio of protective to inflammatory antibody subtypes shifts.

The result: you get more inflammation (from the overactive innate system and exhausted T cells) but less protection (from the declining adaptive system). You're simultaneously inflamed and immunodeficient. This is why older adults are both more susceptible to infections and more prone to chronic inflammatory disease.

This paradox also explains why inflammaging isn't just "too much immunity." It's a qualitative shift -- from targeted, resolving inflammation toward diffuse, persistent inflammation.

Key Takeaway: hsCRP below 0.5 mg/L is the optimal target — standard lab "normal" ranges (below 1.0 or 3.0) are disease-absence thresholds, not health-optimization targets. Supplement with IL-6, TNF-alpha, and fasting insulin measurements for a more complete inflammatory picture. Test every 3-6 months to track your trajectory.

How anti-inflammatory interventions compare:

Anti-Inflammatory Compounds: What the Evidence Supports

Given that inflammaging is driven by multiple sources and operates through identifiable molecular pathways, several natural compounds have been studied for their ability to interrupt these pathways.

Omega-3 Fatty Acids (EPA/DHA)

The omega-3 fatty acids EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) are anti-inflammatory through two mechanisms:

1. Competition with omega-6 arachidonic acid. Both omega-3 and omega-6 fatty acids are substrates for the same COX and LOX enzymes that produce inflammatory mediators. When omega-3s are abundant, they compete with arachidonic acid (an omega-6 fatty acid that is the precursor to pro-inflammatory prostaglandins and leukotrienes), reducing the production of pro-inflammatory prostaglandins (PGE2) and leukotrienes (LTB4).

2. Specialized Pro-Resolving Mediators (SPMs). This is the more important mechanism. EPA and DHA are converted into a class of molecules called SPMs -- resolvins, protectins, and maresins -- that actively resolve inflammation rather than merely suppressing it. SPMs signal macrophages to switch from inflammatory (M1) to repair (M2) phenotype and promote the clearance of cellular debris.

Serhan et al. (2002, Journal of Experimental Medicine) discovered the resolvin pathway and showed that it's not the suppression of pro-inflammatory signals but the active production of pro-resolving signals that determines whether inflammation resolves or becomes chronic. Inflammaging may partly reflect a deficit in SPM production.

A 2019 meta-analysis of 68 RCTs (Guo et al., Cytokine) found that omega-3 supplementation (at doses of 1-4 g/day EPA+DHA) significantly reduced CRP, IL-6, and TNF-alpha in adults with chronic inflammatory conditions.

For a complete look at omega-3 mechanisms, see Omega-3 and Longevity: Beyond Heart Health.

Quercetin and Fisetin (Senolytic SASP Reduction)

Since senescent cell SASP is the largest contributor to inflammaging, compounds that clear senescent cells -- senolytics -- are arguably the most direct anti-inflammaging intervention.

Fisetin -- a flavonoid found in strawberries, apples, and persimmons -- was identified as the most potent natural senolytic in a head-to-head screen of 10 flavonoids by Yousefzadeh et al. (2018, EBioMedicine). In aged mice, fisetin reduced senescent cell burden, lowered SASP-associated inflammatory markers, and extended median lifespan by approximately 10%. The Mayo Clinic's AFFIRM-LITE trial (NCT03675724) is testing fisetin in humans.

Quercetin -- paired with dasatinib (D+Q) in clinical protocols -- was used in the first human senolytic trial (Justice et al. 2019, EBioMedicine), which showed significant reduction in senescent cell markers after just 3 days of treatment. Quercetin also directly inhibits NF-kappaB signaling, providing anti-inflammatory effects independent of its senolytic activity.

Quercetin's bioavailability challenge is significant -- standard oral absorption is approximately 2%. Phytosome formulations (quercetin complexed with sunflower phospholipids) increase absorption by roughly 20-fold.

The logic for inflammaging is straightforward: fewer senescent cells means less SASP, which means less systemic inflammation. Rather than blocking the inflammatory signals downstream, senolytics eliminate the source.

Resveratrol (NF-kappaB Inhibition)

Resveratrol -- the polyphenol found in grape skins, red wine, and Japanese knotweed -- has a well-documented anti-inflammatory mechanism: inhibition of the NF-kappaB signaling pathway.

NF-kappaB is the master transcription factor for inflammatory gene expression. When activated (by TLR signaling, TNF-alpha, IL-1beta, or oxidative stress), it translocates to the nucleus and turns on genes encoding IL-6, TNF-alpha, IL-1beta, COX-2, and iNOS. NF-kappaB is constitutively activated at higher levels in aged tissues compared to young tissues.

Resveratrol inhibits NF-kappaB through multiple mechanisms:

• Activation of SIRT1, which deacetylates the p65 subunit of NF-kappaB, reducing its transcriptional activity
• Activation of AMPK (AMP-activated protein kinase -- an energy-sensing enzyme that promotes repair and suppresses inflammation), which inhibits NF-kappaB through IKK (IkappaB kinase) suppression
• Direct inhibition of IKK, preventing NF-kappaB nuclear translocation
• Activation of Nrf2 (nuclear factor erythroid 2-related factor 2 -- a transcription factor that activates the body's antioxidant defense genes), which produces antioxidant enzymes that reduce the oxidative stress that triggers NF-kappaB

A 2022 meta-analysis of 30 RCTs (Koushki et al., Clinical Nutrition) found that resveratrol supplementation significantly reduced CRP (weighted mean difference: -0.55 mg/L), TNF-alpha, and IL-6 in human subjects. The effects were most pronounced at doses of 150-500 mg/day for durations exceeding 12 weeks.

Berberine (AMPK Activation)

Berberine -- an alkaloid from goldenseal, Oregon grape, and barberry -- activates AMPK, the cellular energy sensor that suppresses inflammatory signaling when activated.

AMPK activation by berberine:

• Inhibits NF-kappaB through multiple pathways (SIRT1 activation, IKK suppression, reduced mTOR signaling)
• Promotes autophagy, which clears damaged mitochondria that would otherwise release inflammatory DAMPs
• Improves insulin sensitivity, reducing the metabolic inflammation driven by insulin resistance
• Modulates the gut microbiome, increasing butyrate-producing bacteria

Zhang et al. (2014, PLoS ONE) demonstrated that berberine (1,500 mg/day) reduced CRP by 32% in patients with metabolic syndrome over 12 weeks -- comparable to metformin. Berberine's effects on inflammaging are likely mediated through both direct AMPK activation and indirect microbiome modulation.

Key Takeaway: The evidence-supported anti-inflammatory compounds target different nodes of the inflammatory cascade: fisetin and quercetin clear the senescent cells that produce SASP, apigenin inhibits NF-kB and CD38, omega-3s produce specialized pro-resolving mediators (SPMs), and resveratrol activates AMPK while suppressing inflammatory transcription factors. A multi-compound approach addresses more sources simultaneously.

Lifestyle Interventions: The First Line of Defense

Compounds matter, but lifestyle interventions have the largest effect sizes for inflammaging reduction.

Exercise: The IL-6 Paradox

Exercise produces one of the most fascinating paradoxes in inflammaging science: muscle contraction releases IL-6 -- the same cytokine that's a hallmark of chronic inflammation -- yet regular exercise is profoundly anti-inflammatory.

The resolution lies in context and kinetics. When IL-6 is released chronically at low levels by senescent cells and visceral fat, it drives inflammatory signaling through classical NF-kappaB pathways. When IL-6 is released acutely in large bursts by contracting muscle (a context where it's classified as a myokine -- a signaling molecule released by muscle tissue during contraction), it has the opposite effect:

• Muscle-derived IL-6 stimulates production of the anti-inflammatory cytokines IL-10 and IL-1ra (IL-1 receptor antagonist -- a molecule that blocks IL-1 signaling)
• It inhibits TNF-alpha production
• It improves insulin sensitivity and promotes fat oxidation
• It stimulates cortisol release, which has short-term anti-inflammatory effects

Pedersen and Febbraio (2008, Nature Reviews Immunology) established the myokine concept, demonstrating that skeletal muscle is an endocrine organ that releases anti-inflammatory signals during contraction. A single bout of exercise can increase circulating IL-6 by 100-fold -- but unlike chronic IL-6 elevation, this spike resolves within hours and leaves anti-inflammatory mediators elevated for days.

Long-term: a 2017 meta-analysis of 37 RCTs in the British Journal of Sports Medicine found that regular exercise (3+ sessions/week, moderate-to-vigorous) reduced CRP by 22-30% and IL-6 by 16-25% in sedentary adults.

Both resistance training and aerobic exercise are effective. For a comprehensive guide to exercise and aging, see Exercise and Longevity: What Actually Works.

Caloric Restriction and Time-Restricted Eating

Caloric restriction (CR) is the most replicated anti-inflammatory intervention in model organisms. The CALERIE trial (Ravussin et al., 2015, JAMA Internal Medicine) -- the first controlled CR study in healthy humans -- showed that caloric restriction (targeting 25%, achieving approximately 12-14% in practice) over two years significantly reduced CRP, TNF-alpha, and improved multiple markers of cardiometabolic health.

The mechanisms are multiple: CR reduces visceral fat (source #3), activates AMPK and sirtuins (which suppress NF-kappaB), enhances autophagy (clearing damaged mitochondria and senescent cells), and reduces metabolic ROS production.

Time-restricted eating (eating within a 6-10 hour window) shows similar, though smaller, effects on inflammatory markers. Wilkinson et al. (2020, Cell Metabolism) found that 10-hour time-restricted eating for 12 weeks reduced hs-CRP by 13% in patients with metabolic syndrome.

Sleep

Sleep deprivation is a potent inflammagen. Even a single night of short sleep (4 hours) increases IL-6, TNF-alpha, and CRP the following day. Irwin et al. (2016, Biological Psychiatry) conducted a meta-analysis of 72 studies and found that sleep disturbance was associated with significant increases in CRP (+40%) and IL-6 (+24%).

The mechanism involves activation of the sympathetic nervous system and HPA axis (hypothalamic-pituitary-adrenal axis -- the body's central stress response system), increased NF-kappaB activation in immune cells, and disruption of the normal circadian regulation of immune function (the immune system has its own circadian rhythm, with inflammatory cytokine production normally suppressed during sleep).

Chronic sleep deprivation also accelerates senescent cell accumulation, which feeds back into SASP-driven inflammation.

Stress Management

Psychological stress activates the same NF-kappaB inflammatory pathways as physical stressors. Powell et al. (2013, PNAS) showed that chronic social stress in animal models increased NF-kappaB activation in monocytes and elevated circulating inflammatory markers -- an effect that persisted long after the stressor was removed.

Meditation, specifically mindfulness-based stress reduction (MBSR), has been shown to reduce NF-kappaB-related gene expression in multiple randomized trials. Creswell et al. (2012, Brain, Behavior, and Immunity) found that an 8-week MBSR program reduced inflammatory gene expression in older adults.

Testing Your Inflammatory Status

If inflammaging is silent, testing is essential. Here are the markers worth tracking.

Essential (Widely Available)

• hs-CRP: The foundational inflammaging marker. Any standard lab can run it. Cost: typically $10-30. Test fasted, avoid testing within 2 weeks of acute illness or injury (which will spike CRP regardless of baseline). Target: < 1.0 mg/L.
• Fasting insulin: Not a direct inflammatory marker, but insulin resistance and inflammation are tightly linked. Elevated fasting insulin (> 8 uIU/mL) often accompanies elevated inflammatory markers. Target: 2-6 uIU/mL.

Advanced (Specialty Panels)

• IL-6: More directly reflects inflammaging than CRP (since CRP is downstream of IL-6). Available through specialty labs. Target: < 2 pg/mL.
• TNF-alpha: Particularly useful if you have significant visceral fat or metabolic syndrome. Target: < 1.0 pg/mL.
• Homocysteine: An amino acid that, when elevated (> 10 umol/L), independently drives endothelial inflammation and is linked to cardiovascular risk. Target: < 8 umol/L.
• Fibrinogen: An acute-phase protein linked to cardiovascular inflammation. Elevated levels (> 400 mg/dL) correlate with CRP.

Emerging

• GlycA: A nuclear magnetic resonance (NMR)-based composite marker of multiple acute-phase glycoproteins. Some researchers argue it captures inflammaging more comprehensively than any single marker. Available through select NMR lipid panels.
• Omega-3 Index: Measures EPA + DHA as a percentage of red blood cell membrane fatty acids. An index below 4% is associated with higher inflammatory markers; above 8% is optimal. Available through dried blood spot testing.

Testing Strategy

A practical approach: test hs-CRP every 6-12 months as your baseline inflammaging metric. If elevated (> 1.0 mg/L), add IL-6 and fasting insulin to identify the source pattern. Retest after 3-6 months of intervention (exercise, dietary changes, targeted compounds) to track response.

Frequently Asked Questions

Related Reading

• Senescent Cells Explained: The Zombie Cells Aging You Faster
• Fisetin: The Most Potent Natural Senolytic Compound
• The 12 Hallmarks of Aging: Why You Age and What Targets Each One
• Omega-3 and Longevity: Beyond Heart Health
• Gut Microbiome and Longevity: What Your Bacteria Have to Do With Aging
• Sulforaphane: The Broccoli Compound That Activates Your Body's Defense System
• Apigenin: CD38 Inhibitor, Sleep Support, and NAD+ Protector
• Myokines: How Your Muscles Talk to Your Brain, Bones, and Immune System

These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.